Sermorelin vs Tesamorelin

Sermorelin and Tesamorelin belong to the same group. Both are synthetic forms of a natural hormone called GHRH. GHRH tells the pituitary gland to release growth hormone (GH). Their design, lifespan, and approvals, however, differ.

Sermorelin is a chain of 29 amino acids. It copies the key part of natural GHRH that binds to its receptor [PMID: 18031173]. The FDA first approved it in 1997 to test for GH deficiency. Because of this, many human studies exist on this peptide.

Tesamorelin is a 44-amino-acid peptide. A chemical group at its start blocks a body enzyme. This change lets the peptide last for hours instead of minutes. The FDA approved it in 2010 to lower belly fat in people with HIV [PMID: 20101189]. Its approved use is more specific than Sermorelin's.

Knowing where the peptides match and differ helps researchers. The choice is not about which is 'better.' It is about matching the peptide to the research goal.

Both peptides have the same target: the GHRH receptor on pituitary cells. When either peptide binds, it triggers a chain of events inside the cell. This process releases stored growth hormone (GH) in pulses [PMID: 18031173].

The main difference is how long they last in the body. An enzyme called DPP-IV quickly breaks down Sermorelin. It removes two small pieces from the peptide's start. This happens within minutes of an injection. The peptide's life is then only 11 to 12 minutes [PMID: 18031173]. Frequent shots are needed to keep the effect going.

Tesamorelin has a chemical group that blocks the DPP-IV enzyme. This protects the peptide, letting it last much longer. Its life is about 26 to 38 minutes in the blood and 4 to 5 hours under the skin [PMID: 19243281]. This longer effect means more steady GH release from one shot.

Both peptides cause the same results from GH. The liver makes more IGF-1, and the body breaks down more fat. However, Tesamorelin's longer action has a stronger effect on belly fat. In one large trial, it reduced belly fat by about 15% over 26 weeks [PMID: 20101189]. Sermorelin's shorter action is better for copying natural GH pulses.

Both peptides keep the body's natural safety check. GH signals the brain to make less GHRH, and IGF-1 signals the pituitary to make less GH. This is a safety plus compared to taking GH directly [PMID: 9141536].

Sermorelin and Tesamorelin both use the same receptor to tell the pituitary to release GH. Neither one adds extra GH to the body. Both make the body's own cells release what they already store. This keeps the body's natural safety controls in place.

Both peptides lead to the same results. The liver makes more IGF-1, and fat is broken down. Both are taken with a shot under the skin. Both have been studied in humans, which is rare for research peptides. Their side effects are also similar: skin reactions, flushing, joint pain, or swelling.

Both peptides also share a limit. They need a healthy pituitary gland to work. If the pituitary is badly damaged, the peptides will not release GH. This limit is also a safety feature. The body's own controls are not bypassed.

How long the peptide lasts is the main difference. Sermorelin lasts only 11 to 12 minutes, so it needs a daily or twice-daily shot. Tesamorelin lasts 4 to 5 hours. One daily shot keeps GH and IGF-1 levels up all day.

Their size also differs. Sermorelin has 29 amino acids, while Tesamorelin has 44. Tesamorelin also has a chemical group that stops an enzyme. This design gives Tesamorelin its longer life.

Their FDA status is another key difference. Sermorelin was approved for GH tests but is no longer sold in the US. Tesamorelin (Egrifta) is still sold for a specific use in people with HIV. It has more clear data from large human trials.

The research focus for each peptide differs. Sermorelin research often looks at GH tests and copying natural GH pulses. Tesamorelin research often looks at belly fat and body composition. A 2010 trial showed Tesamorelin lowered belly fat more than other fat [PMID: 20101189].

Their side effects are similar but differ in strength. Tesamorelin's longer action can cause more joint pain, swelling, or high blood sugar. Sermorelin's side effects are briefer, but shots are more often. The real choice is between timing and convenience.

Choose Sermorelin if your research needs short, sharp GH pulses like the body's own. Its short life copies natural GH release. This is useful for studies on sleep, body clocks, or pituitary function. It is also good for a quick GH test of pituitary function.

Choose Tesamorelin if your research needs long, steady GH and IGF-1 levels. This is needed to break down belly fat over many hours. Large trials in people with HIV show this effect [PMID: 20101189]. It also needs only one shot a day, unlike the more frequent shots for Sermorelin.

For research on aging, the choice depends on the idea behind it. If copying a young body's GH pulses is the goal, Sermorelin is more like the real thing. If steady, mild GH levels are the goal, Tesamorelin does this more reliably.

Neither peptide is for research that needs very high GH levels. Both depend on a healthy pituitary and cannot override the body's controls.